BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32146375)

  • 21. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
    Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
    Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
    Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
    Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
    Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
    Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
    Dong XW; Zhang JK; Xu L; Che JX; Cheng G; Hu XB; Sheng L; Gao AH; Li J; Liu T; Hu YZ; Zhou YB
    Eur J Med Chem; 2019 Feb; 164():602-614. PubMed ID: 30639896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
    Wu LT; Jiang Z; Shen JJ; Yi H; Zhan YC; Sha MQ; Wang Z; Xue ST; Li ZR
    Eur J Med Chem; 2016 May; 114():328-36. PubMed ID: 27017265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
    Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
    Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
    Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS
    Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
    Uysal S; Soyer Z; Saylam M; Tarikogullari AH; Yilmaz S; Kirmizibayrak PB
    Eur J Med Chem; 2021 Jan; 209():112890. PubMed ID: 33039723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
    Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
    Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
    Zhang J; Gao L; Xi J; Sheng L; Zhao Y; Xu L; Shao Y; Liu S; Zhuang R; Zhou Y; Li J
    Bioorg Med Chem; 2016 Dec; 24(23):6206-6214. PubMed ID: 27765408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.
    Wang H; Wu Z; Cao Y; Gao L; Shao J; Zhao Y; Zhang J; Zhou Y; Wei G; Li J; Zhu H
    Bioorg Chem; 2023 Sep; 138():106626. PubMed ID: 37295239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of a novel class of furan-based molecules as potential 20S proteasome inhibitors.
    Fu Y; Xu B; Zou X; Ma C; Yang X; Mou K; Fu G; Lü Y; Xu P
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1102-6. PubMed ID: 17134894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.